FLNA Filana Therapeutics (FLNA) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001069530
C-suite buying · 1
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
26
13F, latest reported quarter
What the filings say about FLNA
Insiders, 180 days
+$356.3K net bought
1 buyer
Filana Therapeutics insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, FILANA THERAPEUTICS, INC. insiders bought a net $356.3K of stock across 3 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Sep 29, 2026.
- The trade is 7.5% of the 1,337,964 shares held after it.
- No other insider bought within 30 days.
- 26 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President & CEO Barry Richard bought about $92.0K of FLNA on Sep 30, 2026; 26 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Sep 28, 2026.
- The trade is 16.7% of the 1,237,964 shares held after it.
- No other insider bought within 30 days.
- 26 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President & CEO Barry Richard bought about $186.1K of FLNA on Sep 29, 2026, the largest insider purchase at the company on our record; 26 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 9.0% of the 1,031,151 shares held after it.
- No other insider bought within 30 days.
- 26 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President & CEO Barry Richard bought about $78.2K of FLNA on Sep 28, 2026, the largest insider purchase at the company on our record; 26 funds added in the latest 13F quarter.3 transactions on record · a thin record, read with care
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net +$356.3K over 180 days
+$356.3K over 90 days
more than 83% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
26 funds bought in last quarter
below 64% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
12.5% of the float short (float per yahoo 2026-10-26) · 1.0 days to cover · settled 2026-09-30
more than 78% of Pharma & Biotech
What changed in the last 30 days
Oct 1President & CEO Barry Richard bought $356.3K (3 trades, Sep 28 to Sep 30)
Watch FLNA
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
Who owns FLNA: institutional holders (13F)
13F holdings, latest reported quarter
1,974,981 sh
$2.4M
1,711,358 sh
$2.0M
1,597,548 sh
$1.9M
1,453,561 sh
$1.7M
668,792 sh
$795.9K
Congress trades in FLNA
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
FLNA planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
FLNA mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Invesco NASDAQ Future Gen 200 ETF
$51.9K position · as of 2026-05-31
0.3%
iShares Micro-Cap ETF
$176.8K position · as of 2026-06-30
0.0%
1290 VT Micro Cap Portfolio
$11.9K position · as of 2026-06-30
0.0%
Fidelity Flex Small Cap Index Fund
$10.1K position · as of 2026-07-31
0.0%
VANGUARD HEALTH CARE INDEX FUND
$203.5K position · as of 2026-05-31
0.0%
Fidelity Extended Market Index Fund
$435.8K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return · Mr. Barbier
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$1.5M
$1.3M
$824.5K
-93%
n/a
2023
$6.3M
$7.6M
$2.4M
-24%
n/a
2022
$1.1M
$361.4K
$1.2M
+468%
n/a
2021
$1.7M
$8.9M
$671.8K
+740%
n/a
2020
$936.1K
$1.3M
$298.5K
+31%
n/a
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $356.3K bought by insiders over 180 days, 26 funds added last quarter. Each figure is a federal filing, dated the day it went public.
FLNA financials
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Revenue, TTM FLNA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
| Jun 2024 | n/a |
At each fiscal year end
Single quarter
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Net margin, TTM FLNA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
| Jun 2024 | n/a |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$30.4M
operating cash flow minus capex, 2025-04-01 to 2026-03-31
Free cash flow, TTM FLNA
| FY Dec 2025 | -$32.8M |
| FY Dec 2024 | -$117.0M |
| FY Dec 2023 | -$82.4M |
| FY Dec 2022 | -$80.2M |
| FY Dec 2021 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | -$10.2M |
| Sep 2025 | -$6.3M |
| Jun 2025 | -$4.9M |
| Mar 2025 | -$11.3M |
| Dec 2024 | -$61.3M |
| Sep 2024 | -$18.3M |
| Jun 2024 | -$18.3M |
At each fiscal year end
Single quarter
Debt to equity
n/a
no debt line filed
Debt to equity FLNA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
| Jun 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt line filed
Cash flow to debt FLNA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
| Jun 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-79.6%
TTM net income over average of 2025-03-31 and 2026-03-31
Return on equity FLNA
| FY Dec 2025 | -82.7% |
| FY Dec 2024 | -17.2% |
| FY Dec 2023 | -53.3% |
| FY Dec 2022 | -31.7% |
| FY Dec 2021 | -18.7% |
| Mar 2026 | -79.6% |
| Dec 2025 | -82.7% |
| Sep 2025 | -85.4% |
| Jun 2025 | -88.9% |
| Mar 2025 | -70.6% |
| Dec 2024 | -17.2% |
| Sep 2024 | -11.0% |
| Jun 2024 | -8.3% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-62.5%
TTM net income over average of 2025-03-31 and 2026-03-31
Return on assets FLNA
| FY Dec 2025 | -65.9% |
| FY Dec 2024 | -15.7% |
| FY Dec 2023 | -50.3% |
| FY Dec 2022 | -30.4% |
| FY Dec 2021 | -17.9% |
| Mar 2026 | -62.5% |
| Dec 2025 | -65.9% |
| Sep 2025 | -60.0% |
| Jun 2025 | -65.0% |
| Mar 2025 | -49.1% |
| Dec 2024 | -15.7% |
| Sep 2024 | -8.9% |
| Jun 2024 | -7.0% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital FLNA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
| Jun 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-83.7%
operating income (EBIT proxy) over average of 2025-03-31 and 2026-03-31 minus current liabilities
Return on capital employed FLNA
| FY Dec 2025 | -86.6% |
| FY Dec 2024 | -99.9% |
| FY Dec 2023 | -58.0% |
| FY Dec 2022 | -33.2% |
| FY Dec 2021 | -19.0% |
| Mar 2026 | -83.7% |
| Dec 2025 | -86.6% |
| Sep 2025 | -89.6% |
| Jun 2025 | -93.9% |
| Mar 2025 | -141.6% |
| Dec 2024 | -99.9% |
| Sep 2024 | -83.7% |
| Jun 2024 | -71.7% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
no close on file at or before the as-of date
P/E, trailing FLNA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
| Jun 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
n/a
no close on file at or before the as-of date
Enterprise value FLNA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
| Jun 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
n/a
no close on file at or before the as-of date
FCF yield FLNA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
| Jun 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
no close on file at or before the as-of date
PEG, trailing FLNA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
| Jun 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Operating income | -$95.4M | -$141.4M | -$106.0M | -$80.0M |
| Net income | -$91.0M | -$24.3M | -$97.2M | -$76.2M |
| EPS (diluted) | -1.88 | -1.46 | -2.32 | -1.90 |
| Operating cash flow | -$32.3M | -$116.9M | -$82.0M | -$77.5M |
| Cash | $95.5M | $128.6M | $121.1M | $201.0M |
SEC XBRL, fiscal years, as known on 2026-10-28
FLNA Stock Sonar score 4/7 axes
Find similar shapesCompareFLNA ranks highest on insider conviction (70th percentile) and profitability (36th), and lowest on risk and compliance (31st), among Pharma & Biotech peers.
4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
FLNA filings, in plain words
Are Filana Therapeutics insiders buying or selling FLNA?
In the 180 days to 2026-10-28, Filana Therapeutics insiders were net buyers, a net $356.3K across purchases and sales reported on Form 4, by 1 buyer.
Read the full summary
In the 180 days to 2026-10-28, Filana Therapeutics insiders were net buyers of FLNA, a net $356.3K across purchases and sales reported on Form 4 by 1 buyer. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
